WHO WE ARE
Since 1986 Novapharm Research has become a world leading Research & Development Company based in Sydney Australia involved in the development of infection prevention & control systems as well as technologies across the critical infection prevention vectors of Hand & Skin Asepsis, Hard Surface disinfection & cleaning, enzymatic instrument cleaning & reprocessing, instrument disinfection and Environmental Hygiene.
Novapharm has powerful, original platform technologies in all of the above infection prevention vectors offering, end-to-end infection control platforms.
Since 1986 we have had a proven track record as the source of market leading IP in global Infection Prevention to companies such as J&J, Ecolab, Getinge, Shülke Mayr & 3M. We have developed very strong relationships with critical key global raw material manufacturers that enables early access to new leading ingredients and technologies. The company is ISO 13485 accredited.
Healthcare professionals throughout the world recognise that the in-vitro efficacy of microbial control solutions has little meaning outside the validating context of the laboratory. To this end, Novapharm’s philosophy toward the development of leading infection prevention products and technologies is driven by an outcome based focus in terms of ‘accountable care’, accreditation and patient safety which delivers effective, innovative and comprehensive solutions based on real world work-flow results.
BASED ON OUR PRODUCTS